Page 70 - วารสารการแพทย์แผนไทยและการแพทย์ ทางเลือก ปีที่ 19 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2564

300 วารสารการแพทย์แผนไทยและการแพทย์ ทางเลือก ปีที่ 19 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2564

multicentre trial. Lancet 2020;395(10236):1569-78. anti-COVID drug Can it really help? [Internet]. 1 Jul
25. National Institute of Health. Remdesivir: COVID-19 2021 [cited July 5, 2021]; Available from: https://www.
treatment guideline. [Internet]. April 21, 2021 [cited bangkokbiznews.com/news/detail/946317 (in Thai)
July 5, 2021]; Available from: https://www.covid19treat- 33. BBC News Thai. Ivermectin, a parasitic drug. [Internet].
mentguidelines.nih.gov/therapies/antiviral-therpay/ March 28, 2021 [cited July 10, 2021]; Available from:
remdesivir/ https://www.bbc.com/thai/international-56549526
26. Rochwerg B, Agarwal A, Zeng L, Leo Y-S, Appiah JA, 34. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova
Agoritsas T, Bartoszko J, Brignardello-Petersen R, Ergan VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Kara-
B, Ge L, Geduld H, Gershengorn HB, Manai H, Huang M, petian RN, Kravchenko DV, Lomakin NV, Merkulova
Lamontagne F, Kanda S, Kawano-Dourado L, Kurian L, EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina
Kwizera A, Murthy S, Qadir N, Siemieniuk R, Silvestre EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG,
MA, Vandvik PO, Ye Z, Zeraatkar D, Guyatt G. Remde- Yakubova EV, Ivachtchenko AV. AVIFAVIR for treat-
sivir for severe covid-19: a clinical practice guideline. ment of patients with moderate COVID-19: interim
BMJ. 2020;370:m2924. results of a phase II/III multicenter randomized clinical
27. World Health Organization. Therapeutics and COVID-19: trial. Clin.Infect. Dis. 2021;73(3):531-4.
living guideline. [Internet]. 2021 [cited July 10, 2021]; 35. Chen PJ, Chao CM, Lai CC. Clinical efficacy and safety of
Available from: https://www.who.int/publications/i/ favipiravir in the treatment ofCOVID-19patients. J.Infect.
item/WHO-2019-nCoV-therapeutics-2021.2 2021;82(5):186-230
28. Siemieniuk RAC, Bartoszko JJ, Ge L, Zeraatkar D, Izco- 36. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H,
vich A, Kum E, Pardo-Hernandez H, Qasim A, Martinez Ebeid FF, Sherief AF, Elgaafary M, Fawzy E, Hassany
JPD, Rochwerg B, Lamontagne F, Han MA, Liu Q, SM, Riad AR, TagelDin MA. Safety and efficacy of
Agarwal A, Agoritsas T, Chu DK, Couban R, Cusano E, favipiravir versus hydroxychloroquine in management
Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, of COVID-19: A randomised controlled trial. Sci. Rep.
Ghadimi M, Heels-Ansdell D, Honarmand K, Hou L, Hou 2021;11:1–7
X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, 37. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y,
McLeod SL, Motaghi S, Murthy S, Mustafa RA, Neary JD, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T,
Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota
Sreekanta A, Switzer C, Tendal B, Thabane L, Tomlinson K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama
G, Turner T, Vandvik PO, Vernooij RW, Viteri-García A, N, Yujiro Uchida Y, Ikeda N, Shinoda M, Nakagawa A,
Wang Y, Yao L, Ye Z, Guyatt GH, Brignardello-Petersen Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A,
R. Drug treatments for COVID-19: living systematic re- Banno S, Koseki T, Teramachi M, Miyata M, Tajima S,
view and network meta-analysis. BMJ. 2020;370:m2980 Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M,
29. ClinicalTrial.gov. [Internet]. April 21, 2021 [cited July 5, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y,
2021]; Available from: https://clinicaltrials.gov/ct2/resul KondoM. A prospective, randomized, open-label trial
ts?recrs=&cond=Covid19&term=Remdesivir&cntry=& of early versus late favipiravir therapy in hospitalized
state=&city=&dist= patients with COVID-19. Antimicrob Agents Chemother.
30. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell 2020;64e01897-20.
S, Hill SR, Tham TC. Ivermectin for prevention and 38. Khamis F, Naabi HA, Lawati AA, Ambusaidi Z, Sharji
treatment of COVID-19 infection: a systematic review, MA, Barwani UA, Pandak N, Balushi ZA, Bahrani MA,
meta-analysis, and trial sequential analysis to inform Salmi IA, Al-Zakwani I. Randomized controlled open
clinical guidelines. Am J Ther. 2021;28(4):e434-60. label trial on the use of favipiravir combined with inhaled
31. Schmith VD, Zhou J, Lobmer LRL. The approved dose interferon beta-1b in hospitalized patients with moder-
of ivermectin alone is not ideal dose for the treatment ate to severe COVID-19 pneumonia. Int. J. Infect. Dis
of COVID-19. Clin Pharmacol Ther. 2020;108(4):762-5. 2021;102:538-43
32. Bangkok Business News. Quality of life team, Get 39. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, Luo R, Yang X, He
to know Ivermectin, a parasitic drug repurposing to L, Lu X, Zhao Q, Liang T, Qiu Y. Clinical outcomes and